maklogo
Market Research Report

Global GMP Cell Banking Market Insights, Size, and Forecast By End Use (Biotechnology Companies, Research Institutions, Pharmaceutical Companies), By Storage Type (Liquid Nitrogen Storage, Mechanical Freezer Storage, Cryopreservation), By Application (Regenerative Medicine, Clinical Research, Tissue Engineering, Pharmaceutical Development), By Cell Type (Hematopoietic Stem Cells, Mesenchymal Stem Cells, Epithelial Stem Cells, Neural Stem Cells), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Key Companies, Competitive Analysis, Trends, and Projections for 2026-2035

Report ID:19062
Published Date:Jan 2026
No. of Pages:223
Base Year for Estimate:2025
Format:
Customize Report

Key Market Insights

Global GMP Cell Banking Market is projected to grow from USD 16.8 Billion in 2025 to USD 71.5 Billion by 2035, reflecting a compound annual growth rate of 14.2% from 2026 through 2035. This market encompasses the process of preserving and storing various cell types under Good Manufacturing Practices (GMP) to ensure their quality, safety, and efficacy for therapeutic, research, and diagnostic applications. It includes services and products related to the procurement, processing, testing, and cryogenic storage of master and working cell banks. The escalating demand for cell and gene therapies, a surge in chronic diseases requiring advanced treatments, and significant advancements in biotechnology and regenerative medicine are primary market drivers. These factors are fueling investments in robust cell banking infrastructure to support clinical trials and commercialization of new therapeutics. Furthermore, the increasing focus on personalized medicine and the development of sophisticated cell-based assays contribute significantly to market expansion. Strict regulatory guidelines governing cell banking operations, while ensuring product safety, also drive the adoption of GMP-compliant facilities and services.

Global GMP Cell Banking Market Value (USD Billion) Analysis, 2025-2035

maklogo
14.2%
CAGR from
2025 - 2035
Source:
www.makdatainsights.com

Key market trends include the widespread adoption of automated cell banking systems, enhancing efficiency and reducing human error, alongside a growing emphasis on induced pluripotent stem cells (iPSCs) for drug discovery and disease modeling. The market is also witnessing a rising number of strategic collaborations and partnerships among pharmaceutical companies, Contract Research Organizations CROs, and academic institutions to accelerate research and development in cell therapy. However, high initial investment costs for establishing and maintaining GMP-compliant facilities, coupled with complex regulatory approval processes, present notable market restraints. Ethical considerations surrounding the use of certain cell types and the technical challenges associated with long-term cell viability and quality assurance also pose significant hurdles. Despite these challenges, the expanding pipeline of cell and gene therapy products and the increasing incidence of various cancers and genetic disorders create substantial market opportunities for innovative solutions and expanded service offerings.

North America currently dominates the global GMP cell banking market, driven by a well-established biotechnology and pharmaceutical industry, extensive R&D activities, strong government support for regenerative medicine, and the presence of numerous key players and advanced healthcare infrastructure. The region benefits from a high adoption rate of advanced therapies and substantial funding for research initiatives. Conversely, Asia Pacific is anticipated to be the fastest-growing region, propelled by improving healthcare infrastructure, increasing prevalence of chronic diseases, a burgeoning patient population, and rising government investments in biotechnological research. Furthermore, the presence of a cost-effective manufacturing landscape and a growing number of clinical trials in countries like China and India are contributing to its rapid expansion. Leading players such as Eli Lilly and Company, Celltex Therapeutics, Ncardia, and Lonza are strategically focusing on expanding their GMP-compliant facilities, forging strategic alliances, and investing in advanced technologies to enhance their service portfolios and strengthen their market presence globally. These strategies are aimed at addressing the evolving needs of the cell and gene therapy landscape and capitalizing on emerging opportunities.

Quick Stats

  • Market Size (2025):

    USD 16.8 Billion

  • Projected Market Size (2035):

    USD 71.5 Billion

  • Leading Segment:

    Hematopoietic Stem Cells (42.8% Share)

  • Dominant Region (2025):

    North America (38.7% Share)

  • CAGR (2026-2035):

    14.2%

What is GMP Cell Banking?

GMP Cell Banking involves the creation and storage of master and working cell banks under Good Manufacturing Practices. This process ensures the consistent quality, identity, and purity of cell lines used in biopharmaceutical production, cell and gene therapy, and vaccine manufacturing. By meticulously characterizing, testing, and cryopreserving cells, GMP cell banking minimizes contamination risks and genetic drift. It provides a robust, well documented, and renewable source of cells, essential for product consistency, regulatory compliance, and the safety and efficacy of therapeutic products. This foundational step safeguards future manufacturing needs.

What are the Trends in Global GMP Cell Banking Market

  • Automated Systems Drive Efficiency

  • AI Integration for Quality Control

  • Decentralized Banking Networks

  • Sustainable Practices in Cell Storage

Automated Systems Drive Efficiency

Automated systems are transforming GMP cell banking by streamlining operations. They enhance precision and reduce human error in critical processes like cell expansion and cryopreservation. This automation ensures consistent quality and compliance with regulatory standards, significantly boosting efficiency and throughput. Laboratories are adopting these systems to improve data integrity, traceability, and overall operational reliability, thereby accelerating research and therapeutic development.

AI Integration for Quality Control

AI integration for quality control in cell banking revolutionizes the market. It enhances consistency and reduces human error during cell characterization and lot release. This trend involves using AI powered systems for automated image analysis, anomaly detection, and real time monitoring of critical process parameters. Such precision ensures higher quality and safety of banked cells, accelerating therapies.

Decentralized Banking Networks

Decentralized banking networks offer a paradigm shift for GMP cell banking. They enable peer to peer transactions and verifiable record keeping through blockchain technology. This increases transparency traceability and security of cell line data and financial transactions. It potentially reduces reliance on traditional intermediaries streamlining data management and accelerating access to new cell lines and therapies globally.

Sustainable Practices in Cell Storage

Sustainable practices in cell storage are trending towards minimizing environmental impact within GMP cell banking. This involves optimizing energy consumption for cryopreservation, reducing hazardous waste generation, and exploring greener alternatives for consumables and reagents. The focus is on implementing eco friendly methods throughout the entire cell storage lifecycle, ensuring both product integrity and environmental stewardship, reflecting a commitment to long term ecological responsibility in biotechnology operations.

What are the Key Drivers Shaping the Global GMP Cell Banking Market

  • Rising Demand for Biologics and Advanced Therapies

  • Stringent Regulatory Landscape and Quality Standards

  • Technological Advancements in Cell Banking Automation and Preservation

  • Increasing R&D Investments and Biopharmaceutical Pipeline Expansion

Rising Demand for Biologics and Advanced Therapies

The expanding pipeline and commercialization of biologics and advanced therapies like cell and gene therapies fuel a surge in demand for specialized GMP cell banking. These complex products require robust, compliant cell lines and master cell banks, driving the need for secure, high-quality storage solutions to ensure product safety, efficacy, and consistent manufacturing for patients worldwide. This rising demand is a key market driver.

Stringent Regulatory Landscape and Quality Standards

Strict global regulations from authorities like FDA and EMA demand rigorous quality control in cell banking. Compliance with these stringent GMP standards ensures the safety efficacy and purity of cell lines. This necessitates meticulous testing validation and documentation throughout the cell bank's lifecycle driving growth as companies invest to meet these essential requirements for therapeutic development and commercialization.

Technological Advancements in Cell Banking Automation and Preservation

Innovations in automated cell banking systems and advanced preservation techniques are significantly propelling the global GMP cell banking market. These technological leaps enhance efficiency, reduce human error, and ensure consistent quality and viability of banked cells. This progress drives wider adoption and expansion of cell banking services worldwide.

Increasing R&D Investments and Biopharmaceutical Pipeline Expansion

Growing R&D in biopharmaceuticals drives demand for GMP cell banking. As drug discovery expands, robust cell banks are crucial for consistent starting materials in clinical trials and manufacturing. This ensures product quality, safety, and regulatory compliance for novel cell and gene therapies, directly fueling the market's growth.

Global GMP Cell Banking Market Restraints

Stringent Regulatory Hurdles for Allogeneic Cell Banks

Strict regulatory pathways for allogeneic cell banks pose significant market entry barriers. These hurdles encompass rigorous testing requirements, extensive validation protocols, and complex approval processes mandated by global health authorities. Manufacturers face substantial time and resource investments to achieve compliance, slowing market access for new products. This stringent oversight aims to ensure patient safety and product quality, but it simultaneously restrains market expansion and innovation by increasing developmental costs and timelines for allogeneic cell therapies.

High Initial Capital Investment and Operational Costs

Establishing state of the art GMP compliant cell banking facilities demands substantial upfront capital for cleanrooms, specialized equipment, and advanced quality control systems. Ongoing operational expenses are also high, including rigorous environmental monitoring, highly skilled personnel for cell line management and testing, and expensive raw materials. These significant financial commitments restrict market entry for smaller players and limit expansion for existing ones, impacting overall market growth and accessibility.

Global GMP Cell Banking Market Opportunities

Scaling GMP Cell Banking to Power Next-Gen Cell & Gene Therapies

The burgeoning demand from next-generation cell and gene therapies presents a massive opportunity to scale Good Manufacturing Practice GMP cell banking. This involves expanding global infrastructure, particularly in fast-growing regions like Asia Pacific, to create consistent, high-quality cell banks. Scaling ensures a robust supply of critical starting materials, accelerating preclinical research, facilitating clinical trials, and enabling commercial manufacturing of these transformative treatments. Meeting this foundational need powers therapeutic innovation and expands patient access worldwide.

Driving Efficiency via Outsourced GMP Cell Banking for Biopharma

Outsourcing GMP cell banking offers biopharma companies a crucial pathway to enhance operational efficiency. By leveraging specialized contract manufacturing organizations, firms avoid substantial capital investments in facilities and highly trained staff. This strategy accelerates drug development timelines, ensures stringent quality compliance, and enables biopharma to focus on their core R&D activities. It provides scalable, cost effective solutions for vital cell line management, optimizing resource allocation and reducing time to market for innovative therapies globally. This model represents a key opportunity for streamlined biopharmaceutical production and enhanced profitability worldwide.

Global GMP Cell Banking Market Segmentation Analysis

Key Market Segments

By Cell Type

  • •Hematopoietic Stem Cells
  • •Mesenchymal Stem Cells
  • •Epithelial Stem Cells
  • •Neural Stem Cells

By Storage Type

  • •Liquid Nitrogen Storage
  • •Mechanical Freezer Storage
  • •Cryopreservation

By Application

  • •Regenerative Medicine
  • •Clinical Research
  • •Tissue Engineering
  • •Pharmaceutical Development

By End Use

  • •Biotechnology Companies
  • •Research Institutions
  • •Pharmaceutical Companies

Segment Share By Cell Type

Share, By Cell Type, 2025 (%)

  • Hematopoietic Stem Cells
  • Mesenchymal Stem Cells
  • Epithelial Stem Cells
  • Neural Stem Cells
maklogo
$16.8BGlobal Market Size, 2025
Source:
www.makdatainsights.com

Why are Hematopoietic Stem Cells dominating the Global GMP Cell Banking Market?

Hematopoietic Stem Cells lead due to their extensive and well established use in treating various blood related disorders, cancers, and autoimmune diseases. Their proven clinical efficacy in transplantation and therapies drives significant demand for GMP compliant banking. The robust research and development activities further solidify their position as the primary cell type requiring stringent quality control and storage.

How does Storage Type influence the GMP Cell Banking landscape?

Liquid Nitrogen Storage emerges as the preferred method, crucial for maintaining the long term viability and integrity of diverse cell types. Its ability to achieve ultra low temperatures minimizes cellular degradation, ensuring that banked cells retain their therapeutic potential and research utility. This reliability is paramount for applications demanding high quality, viable cell populations.

Which Application segment is a key driver for GMP Cell Banking demand?

Regenerative Medicine significantly propels the GMP Cell Banking market, driven by the increasing number of cell based therapies undergoing clinical trials and regulatory approval. This segment necessitates large quantities of consistently high quality cells for developing treatments for tissue repair and disease management, underscoring the critical need for robust GMP compliant banking solutions.

What Regulatory and Policy Factors Shape the Global GMP Cell Banking Market

The global GMP cell banking market navigates a complex regulatory landscape requiring stringent adherence to evolving quality standards. Agencies such as the FDA, EMA, and national health authorities enforce comprehensive Good Manufacturing Practices for manufacturing, testing, and release of cell banks. Key guidelines like ICH Q5A for viral safety and Pharmacopoeial standards dictate critical control points. Traceability, robust documentation, and quality risk management are paramount. Harmonization efforts persist, yet regional differences in requirements for investigational and commercial products demand careful navigation. Advanced therapies amplify scrutiny, driving a focus on donor eligibility, facility qualification, and contamination control, ensuring product safety and efficacy worldwide.

What New Technologies are Shaping Global GMP Cell Banking Market?

Innovations are rapidly transforming GMP cell banking. Advanced automation and robotic systems significantly enhance scalability, reduce human error, and ensure consistent quality across cell line production and storage. Emerging cryopreservation techniques, including novel cryoprotectants and controlled rate freezing advancements, improve cell viability and recovery post thaw, critical for sensitive therapeutic cells. Digitalization and artificial intelligence are integrating for real time monitoring, predictive analytics, and robust quality control, optimizing inventory management and compliance. Blockchain technology offers unprecedented transparency and traceability throughout the cell's lifecycle, bolstering data integrity and regulatory adherence. These technologies collectively drive greater efficiency, safety, and reliability in supporting the burgeoning cell and gene therapy pipeline.

Global GMP Cell Banking Market Regional Analysis

Global GMP Cell Banking Market

Trends, by Region

Largest Market
Fastest Growing Market
maklogo
38.7%

North America Market
Revenue Share, 2025

Source:
www.makdatainsights.com

North America dominates the GMP cell banking market, holding a substantial 38.7% share. This leadership is driven by several key factors. The region boasts a strong presence of major biotechnology and pharmaceutical companies, coupled with significant investments in cell and gene therapy research and development. An advanced healthcare infrastructure, readily available funding for R&D, and supportive regulatory frameworks further accelerate market growth. The high adoption rate of advanced therapies and a robust academic research landscape also contribute significantly to North America's stronghold in the global GMP cell banking market.

Europe is a leading force in the GMP cell banking market, driven by robust biotech and pharmaceutical industries, strong regulatory frameworks (EMA), and significant R&D investment. Countries like Germany, UK, France, and Switzerland are key hubs, boasting advanced research infrastructure, numerous academic institutions, and a growing number of Contract Manufacturing Organizations (CMOs). Increasing demand for advanced therapies, coupled with government initiatives supporting regenerative medicine, further propels market expansion. The region's focus on quality, safety, and innovation ensures sustained growth and a competitive edge in the global landscape.

Asia Pacific is the fastest-growing region in the GMP Cell Banking Market, exhibiting a remarkable 19.2% CAGR. This surge is driven by expanding biotechnology and pharmaceutical sectors, increasing R&D investments, and a rising prevalence of chronic diseases necessitating advanced therapies. Countries like China, India, South Korea, and Japan are at the forefront, establishing state-of-the-art cell banking facilities and fostering innovation. Government initiatives supporting stem cell research and regenerative medicine further propel market expansion. The growing demand for personalized medicine and cell therapies, coupled with a large patient pool, positions Asia Pacific as a critical hub for GMP cell banking.

Latin America's GMP cell banking market is burgeoning, fueled by increasing biotech investments and a growing number of clinical trials. Countries like Brazil, Mexico, and Argentina are emerging as regional hubs, driven by advancements in regenerative medicine and gene therapies. Local governments are implementing supportive regulatory frameworks to attract foreign investment and foster domestic innovation. The rising prevalence of chronic diseases and demand for advanced therapies further propels market expansion. Challenges include a nascent regulatory landscape in some smaller nations and the need for greater awareness and skilled personnel. However, the region presents substantial growth potential for both local and international players.

The Middle East & Africa GMP cell banking market is experiencing dynamic growth, driven by increasing healthcare expenditure, rising prevalence of chronic diseases, and growing focus on personalized medicine and advanced therapies. South Africa, Saudi Arabia, and UAE are leading the regional market, investing heavily in biotechnology and pharmaceutical infrastructure. The lack of stringent regulatory frameworks and limited skilled workforce in certain regions pose challenges. However, government initiatives promoting biomedical research and international collaborations are creating significant opportunities. The market is witnessing the emergence of regional players and a growing demand for specialized cell banking services, particularly for stem cells and immunotherapy applications.

Top Countries Overview

The United States leads the global GMP cell banking market due to strong biotech and pharma sectors. This market thrives on increasing demand for regenerative medicines and cell therapies, requiring compliant, high quality, accessible cryopreservation services for research and clinical applications across the nation.

China's expanding biotechnology sector fuels its GMP cell banking market. Domestic companies, driven by innovation and regulatory support, are increasingly meeting local demand for high quality master and working cell banks. Global collaborations are also growing, positioning China as a key player in the international cell banking landscape.

India is emerging in global GMP cell banking. It offers skilled workforce and cost efficiency attracting international players. Growing domestic biotech and government support further fuel its expansion positioning India as a key regional hub for therapeutic cell banking services and research advancements.

Impact of Geopolitical and Macroeconomic Factors

Geopolitical stability is crucial for GMP cell banking, facilitating international research collaborations and reducing supply chain disruptions. Trade policies and intellectual property rights influence market entry and technology transfer, particularly for specialized banking services. Regulatory harmonization across nations streamlines compliance and expands market reach for novel cell therapies.

Macroeconomic factors significantly impact investment in cell banking infrastructure and R&D. Economic growth drives increased healthcare spending, including advanced therapies. Inflation can raise operating costs for specialized facilities, affecting profitability. Interest rates influence capital availability for expansion and technological upgrades, crucial for maintaining competitive edge.

Recent Developments

  • March 2025

    Lonza announced a strategic partnership with Celltex Therapeutics to expand its GMP cell banking services for mesenchymal stem cell (MSC) therapies. This collaboration aims to leverage Lonza's global manufacturing network and Celltex's expertise in autologous MSC banking to meet the growing demand for high-quality, compliant cell banks.

  • January 2025

    Merck KGaA launched a new portfolio of advanced cell culture media specifically designed for GMP-compliant manufacturing of allogeneic and autologous cell therapies. These new media formulations aim to optimize cell growth, viability, and potency while adhering to stringent regulatory requirements for global cell banking.

  • February 2025

    Catalent completed the acquisition of a state-of-the-art GMP cell banking facility from Ncardia, significantly expanding its capacity for viral vector and cell therapy manufacturing. This acquisition strategically positions Catalent to offer end-to-end development and manufacturing solutions, including extensive GMP cell banking capabilities, to a broader client base.

  • April 2025

    Cryoport announced a significant investment in expanding its global network of temperature-controlled storage and logistics for GMP cell banks. This strategic initiative involves the opening of new advanced cryogenic storage facilities in key biopharmaceutical hubs, further enhancing their capabilities to support the secure and compliant transport and storage of critical cell materials worldwide.

  • May 2025

    STEMCELL Technologies introduced a new automated system for the cryopreservation and thawing of GMP-grade cell banks, designed to minimize human error and standardize critical steps in cell banking workflows. This product launch aims to improve the consistency and reproducibility of cell bank quality, essential for regulatory compliance and therapeutic efficacy.

Key Players Analysis

Key players in the global GMP Cell Banking market like Lonza and Catalent drive growth through their CDMO services, offering robust solutions for cell line development and cryopreservation. Eli Lilly and Merck KGaA represent pharmaceutical giants leveraging these services for their cell based therapies. Ncardia and STEMCELL Technologies contribute specialized cell types and media, enhancing the quality and consistency of banked cells. Cryoport provides critical cold chain logistics, ensuring product integrity. Companies like Celltex Therapeutics and Iovance Biotherapeutics exemplify therapeutic developers relying on GMP compliant banking for their innovative treatments, fueling market expansion through increasing demand for high quality, secure cell storage for clinical and commercial applications.

List of Key Companies:

  1. Eli Lilly and Company
  2. Celltex Therapeutics
  3. Ncardia
  4. Iovance Biotherapeutics
  5. Merck KGaA
  6. STEMCELL Technologies
  7. Lonza
  8. Cryoport
  9. Celerion
  10. Catalent
  11. MilliporeSigma
  12. Asterand Bioscience
  13. Takeda Pharmaceutical
  14. Thermo Fisher Scientific
  15. BristolMyers Squibb
  16. Fresenius Kabi
  17. WuXi AppTec

Report Scope and Segmentation

Report ComponentDescription
Market Size (2025)USD 16.8 Billion
Forecast Value (2035)USD 71.5 Billion
CAGR (2026-2035)14.2%
Base Year2025
Historical Period2020-2025
Forecast Period2026-2035
Segments Covered
  • By Cell Type:
    • •Hematopoietic Stem Cells
    • •Mesenchymal Stem Cells
    • •Epithelial Stem Cells
    • •Neural Stem Cells
  • By Storage Type:
    • •Liquid Nitrogen Storage
    • •Mechanical Freezer Storage
    • •Cryopreservation
  • By Application:
    • •Regenerative Medicine
    • •Clinical Research
    • •Tissue Engineering
    • •Pharmaceutical Development
  • By End Use:
    • •Biotechnology Companies
    • •Research Institutions
    • •Pharmaceutical Companies
Regional Analysis
  • North America
  • • United States
  • • Canada
  • Europe
  • • Germany
  • • France
  • • United Kingdom
  • • Spain
  • • Italy
  • • Russia
  • • Rest of Europe
  • Asia-Pacific
  • • China
  • • India
  • • Japan
  • • South Korea
  • • New Zealand
  • • Singapore
  • • Vietnam
  • • Indonesia
  • • Rest of Asia-Pacific
  • Latin America
  • • Brazil
  • • Mexico
  • • Rest of Latin America
  • Middle East and Africa
  • • South Africa
  • • Saudi Arabia
  • • UAE
  • • Rest of Middle East and Africa

Table of Contents:

1. Introduction
1.1. Objectives of Research
1.2. Market Definition
1.3. Market Scope
1.4. Research Methodology
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends
4. Market Factor Analysis
4.1. Porter's Five Forces Model Analysis
4.1.1. Rivalry among Existing Competitors
4.1.2. Bargaining Power of Buyers
4.1.3. Bargaining Power of Suppliers
4.1.4. Threat of Substitute Products or Services
4.1.5. Threat of New Entrants
4.2. PESTEL Analysis
4.2.1. Political Factors
4.2.2. Economic & Social Factors
4.2.3. Technological Factors
4.2.4. Environmental Factors
4.2.5. Legal Factors
4.3. Supply and Value Chain Assessment
4.4. Regulatory and Policy Environment Review
4.5. Market Investment Attractiveness Index
4.6. Technological Innovation and Advancement Review
4.7. Impact of Geopolitical and Macroeconomic Factors
4.8. Trade Dynamics: Import-Export Assessment (Where Applicable)
5. Global GMP Cell Banking Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
5.1. Market Analysis, Insights and Forecast, 2020-2035, By Cell Type
5.1.1. Hematopoietic Stem Cells
5.1.2. Mesenchymal Stem Cells
5.1.3. Epithelial Stem Cells
5.1.4. Neural Stem Cells
5.2. Market Analysis, Insights and Forecast, 2020-2035, By Storage Type
5.2.1. Liquid Nitrogen Storage
5.2.2. Mechanical Freezer Storage
5.2.3. Cryopreservation
5.3. Market Analysis, Insights and Forecast, 2020-2035, By Application
5.3.1. Regenerative Medicine
5.3.2. Clinical Research
5.3.3. Tissue Engineering
5.3.4. Pharmaceutical Development
5.4. Market Analysis, Insights and Forecast, 2020-2035, By End Use
5.4.1. Biotechnology Companies
5.4.2. Research Institutions
5.4.3. Pharmaceutical Companies
5.5. Market Analysis, Insights and Forecast, 2020-2035, By Region
5.5.1. North America
5.5.2. Europe
5.5.3. Asia-Pacific
5.5.4. Latin America
5.5.5. Middle East and Africa
6. North America GMP Cell Banking Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
6.1. Market Analysis, Insights and Forecast, 2020-2035, By Cell Type
6.1.1. Hematopoietic Stem Cells
6.1.2. Mesenchymal Stem Cells
6.1.3. Epithelial Stem Cells
6.1.4. Neural Stem Cells
6.2. Market Analysis, Insights and Forecast, 2020-2035, By Storage Type
6.2.1. Liquid Nitrogen Storage
6.2.2. Mechanical Freezer Storage
6.2.3. Cryopreservation
6.3. Market Analysis, Insights and Forecast, 2020-2035, By Application
6.3.1. Regenerative Medicine
6.3.2. Clinical Research
6.3.3. Tissue Engineering
6.3.4. Pharmaceutical Development
6.4. Market Analysis, Insights and Forecast, 2020-2035, By End Use
6.4.1. Biotechnology Companies
6.4.2. Research Institutions
6.4.3. Pharmaceutical Companies
6.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
6.5.1. United States
6.5.2. Canada
7. Europe GMP Cell Banking Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
7.1. Market Analysis, Insights and Forecast, 2020-2035, By Cell Type
7.1.1. Hematopoietic Stem Cells
7.1.2. Mesenchymal Stem Cells
7.1.3. Epithelial Stem Cells
7.1.4. Neural Stem Cells
7.2. Market Analysis, Insights and Forecast, 2020-2035, By Storage Type
7.2.1. Liquid Nitrogen Storage
7.2.2. Mechanical Freezer Storage
7.2.3. Cryopreservation
7.3. Market Analysis, Insights and Forecast, 2020-2035, By Application
7.3.1. Regenerative Medicine
7.3.2. Clinical Research
7.3.3. Tissue Engineering
7.3.4. Pharmaceutical Development
7.4. Market Analysis, Insights and Forecast, 2020-2035, By End Use
7.4.1. Biotechnology Companies
7.4.2. Research Institutions
7.4.3. Pharmaceutical Companies
7.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
7.5.1. Germany
7.5.2. France
7.5.3. United Kingdom
7.5.4. Spain
7.5.5. Italy
7.5.6. Russia
7.5.7. Rest of Europe
8. Asia-Pacific GMP Cell Banking Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
8.1. Market Analysis, Insights and Forecast, 2020-2035, By Cell Type
8.1.1. Hematopoietic Stem Cells
8.1.2. Mesenchymal Stem Cells
8.1.3. Epithelial Stem Cells
8.1.4. Neural Stem Cells
8.2. Market Analysis, Insights and Forecast, 2020-2035, By Storage Type
8.2.1. Liquid Nitrogen Storage
8.2.2. Mechanical Freezer Storage
8.2.3. Cryopreservation
8.3. Market Analysis, Insights and Forecast, 2020-2035, By Application
8.3.1. Regenerative Medicine
8.3.2. Clinical Research
8.3.3. Tissue Engineering
8.3.4. Pharmaceutical Development
8.4. Market Analysis, Insights and Forecast, 2020-2035, By End Use
8.4.1. Biotechnology Companies
8.4.2. Research Institutions
8.4.3. Pharmaceutical Companies
8.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
8.5.1. China
8.5.2. India
8.5.3. Japan
8.5.4. South Korea
8.5.5. New Zealand
8.5.6. Singapore
8.5.7. Vietnam
8.5.8. Indonesia
8.5.9. Rest of Asia-Pacific
9. Latin America GMP Cell Banking Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
9.1. Market Analysis, Insights and Forecast, 2020-2035, By Cell Type
9.1.1. Hematopoietic Stem Cells
9.1.2. Mesenchymal Stem Cells
9.1.3. Epithelial Stem Cells
9.1.4. Neural Stem Cells
9.2. Market Analysis, Insights and Forecast, 2020-2035, By Storage Type
9.2.1. Liquid Nitrogen Storage
9.2.2. Mechanical Freezer Storage
9.2.3. Cryopreservation
9.3. Market Analysis, Insights and Forecast, 2020-2035, By Application
9.3.1. Regenerative Medicine
9.3.2. Clinical Research
9.3.3. Tissue Engineering
9.3.4. Pharmaceutical Development
9.4. Market Analysis, Insights and Forecast, 2020-2035, By End Use
9.4.1. Biotechnology Companies
9.4.2. Research Institutions
9.4.3. Pharmaceutical Companies
9.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of Latin America
10. Middle East and Africa GMP Cell Banking Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
10.1. Market Analysis, Insights and Forecast, 2020-2035, By Cell Type
10.1.1. Hematopoietic Stem Cells
10.1.2. Mesenchymal Stem Cells
10.1.3. Epithelial Stem Cells
10.1.4. Neural Stem Cells
10.2. Market Analysis, Insights and Forecast, 2020-2035, By Storage Type
10.2.1. Liquid Nitrogen Storage
10.2.2. Mechanical Freezer Storage
10.2.3. Cryopreservation
10.3. Market Analysis, Insights and Forecast, 2020-2035, By Application
10.3.1. Regenerative Medicine
10.3.2. Clinical Research
10.3.3. Tissue Engineering
10.3.4. Pharmaceutical Development
10.4. Market Analysis, Insights and Forecast, 2020-2035, By End Use
10.4.1. Biotechnology Companies
10.4.2. Research Institutions
10.4.3. Pharmaceutical Companies
10.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
10.5.1. South Africa
10.5.2. Saudi Arabia
10.5.3. UAE
10.5.4. Rest of Middle East and Africa
11. Competitive Analysis and Company Profiles
11.1. Market Share of Key Players
11.1.1. Global Company Market Share
11.1.2. Regional/Sub-Regional Company Market Share
11.2. Company Profiles
11.2.1. Eli Lilly and Company
11.2.1.1. Business Overview
11.2.1.2. Products Offering
11.2.1.3. Financial Insights (Based on Availability)
11.2.1.4. Company Market Share Analysis
11.2.1.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.1.6. Strategy
11.2.1.7. SWOT Analysis
11.2.2. Celltex Therapeutics
11.2.2.1. Business Overview
11.2.2.2. Products Offering
11.2.2.3. Financial Insights (Based on Availability)
11.2.2.4. Company Market Share Analysis
11.2.2.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.2.6. Strategy
11.2.2.7. SWOT Analysis
11.2.3. Ncardia
11.2.3.1. Business Overview
11.2.3.2. Products Offering
11.2.3.3. Financial Insights (Based on Availability)
11.2.3.4. Company Market Share Analysis
11.2.3.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.3.6. Strategy
11.2.3.7. SWOT Analysis
11.2.4. Iovance Biotherapeutics
11.2.4.1. Business Overview
11.2.4.2. Products Offering
11.2.4.3. Financial Insights (Based on Availability)
11.2.4.4. Company Market Share Analysis
11.2.4.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.4.6. Strategy
11.2.4.7. SWOT Analysis
11.2.5. Merck KGaA
11.2.5.1. Business Overview
11.2.5.2. Products Offering
11.2.5.3. Financial Insights (Based on Availability)
11.2.5.4. Company Market Share Analysis
11.2.5.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.5.6. Strategy
11.2.5.7. SWOT Analysis
11.2.6. STEMCELL Technologies
11.2.6.1. Business Overview
11.2.6.2. Products Offering
11.2.6.3. Financial Insights (Based on Availability)
11.2.6.4. Company Market Share Analysis
11.2.6.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.6.6. Strategy
11.2.6.7. SWOT Analysis
11.2.7. Lonza
11.2.7.1. Business Overview
11.2.7.2. Products Offering
11.2.7.3. Financial Insights (Based on Availability)
11.2.7.4. Company Market Share Analysis
11.2.7.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.7.6. Strategy
11.2.7.7. SWOT Analysis
11.2.8. Cryoport
11.2.8.1. Business Overview
11.2.8.2. Products Offering
11.2.8.3. Financial Insights (Based on Availability)
11.2.8.4. Company Market Share Analysis
11.2.8.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.8.6. Strategy
11.2.8.7. SWOT Analysis
11.2.9. Celerion
11.2.9.1. Business Overview
11.2.9.2. Products Offering
11.2.9.3. Financial Insights (Based on Availability)
11.2.9.4. Company Market Share Analysis
11.2.9.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.9.6. Strategy
11.2.9.7. SWOT Analysis
11.2.10. Catalent
11.2.10.1. Business Overview
11.2.10.2. Products Offering
11.2.10.3. Financial Insights (Based on Availability)
11.2.10.4. Company Market Share Analysis
11.2.10.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.10.6. Strategy
11.2.10.7. SWOT Analysis
11.2.11. MilliporeSigma
11.2.11.1. Business Overview
11.2.11.2. Products Offering
11.2.11.3. Financial Insights (Based on Availability)
11.2.11.4. Company Market Share Analysis
11.2.11.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.11.6. Strategy
11.2.11.7. SWOT Analysis
11.2.12. Asterand Bioscience
11.2.12.1. Business Overview
11.2.12.2. Products Offering
11.2.12.3. Financial Insights (Based on Availability)
11.2.12.4. Company Market Share Analysis
11.2.12.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.12.6. Strategy
11.2.12.7. SWOT Analysis
11.2.13. Takeda Pharmaceutical
11.2.13.1. Business Overview
11.2.13.2. Products Offering
11.2.13.3. Financial Insights (Based on Availability)
11.2.13.4. Company Market Share Analysis
11.2.13.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.13.6. Strategy
11.2.13.7. SWOT Analysis
11.2.14. Thermo Fisher Scientific
11.2.14.1. Business Overview
11.2.14.2. Products Offering
11.2.14.3. Financial Insights (Based on Availability)
11.2.14.4. Company Market Share Analysis
11.2.14.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.14.6. Strategy
11.2.14.7. SWOT Analysis
11.2.15. BristolMyers Squibb
11.2.15.1. Business Overview
11.2.15.2. Products Offering
11.2.15.3. Financial Insights (Based on Availability)
11.2.15.4. Company Market Share Analysis
11.2.15.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.15.6. Strategy
11.2.15.7. SWOT Analysis
11.2.16. Fresenius Kabi
11.2.16.1. Business Overview
11.2.16.2. Products Offering
11.2.16.3. Financial Insights (Based on Availability)
11.2.16.4. Company Market Share Analysis
11.2.16.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.16.6. Strategy
11.2.16.7. SWOT Analysis
11.2.17. WuXi AppTec
11.2.17.1. Business Overview
11.2.17.2. Products Offering
11.2.17.3. Financial Insights (Based on Availability)
11.2.17.4. Company Market Share Analysis
11.2.17.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.17.6. Strategy
11.2.17.7. SWOT Analysis

List of Figures

List of Tables

Table 1: Global GMP Cell Banking Market Revenue (USD billion) Forecast, by Cell Type, 2020-2035

Table 2: Global GMP Cell Banking Market Revenue (USD billion) Forecast, by Storage Type, 2020-2035

Table 3: Global GMP Cell Banking Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 4: Global GMP Cell Banking Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 5: Global GMP Cell Banking Market Revenue (USD billion) Forecast, by Region, 2020-2035

Table 6: North America GMP Cell Banking Market Revenue (USD billion) Forecast, by Cell Type, 2020-2035

Table 7: North America GMP Cell Banking Market Revenue (USD billion) Forecast, by Storage Type, 2020-2035

Table 8: North America GMP Cell Banking Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 9: North America GMP Cell Banking Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 10: North America GMP Cell Banking Market Revenue (USD billion) Forecast, by Country, 2020-2035

Table 11: Europe GMP Cell Banking Market Revenue (USD billion) Forecast, by Cell Type, 2020-2035

Table 12: Europe GMP Cell Banking Market Revenue (USD billion) Forecast, by Storage Type, 2020-2035

Table 13: Europe GMP Cell Banking Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 14: Europe GMP Cell Banking Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 15: Europe GMP Cell Banking Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 16: Asia Pacific GMP Cell Banking Market Revenue (USD billion) Forecast, by Cell Type, 2020-2035

Table 17: Asia Pacific GMP Cell Banking Market Revenue (USD billion) Forecast, by Storage Type, 2020-2035

Table 18: Asia Pacific GMP Cell Banking Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 19: Asia Pacific GMP Cell Banking Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 20: Asia Pacific GMP Cell Banking Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 21: Latin America GMP Cell Banking Market Revenue (USD billion) Forecast, by Cell Type, 2020-2035

Table 22: Latin America GMP Cell Banking Market Revenue (USD billion) Forecast, by Storage Type, 2020-2035

Table 23: Latin America GMP Cell Banking Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 24: Latin America GMP Cell Banking Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 25: Latin America GMP Cell Banking Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 26: Middle East & Africa GMP Cell Banking Market Revenue (USD billion) Forecast, by Cell Type, 2020-2035

Table 27: Middle East & Africa GMP Cell Banking Market Revenue (USD billion) Forecast, by Storage Type, 2020-2035

Table 28: Middle East & Africa GMP Cell Banking Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 29: Middle East & Africa GMP Cell Banking Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 30: Middle East & Africa GMP Cell Banking Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Frequently Asked Questions

Industry

Financial Services Market Research

Explore comprehensive market research reports covering all aspects of the Financial Services industry, including market size, growth trends, competitive landscape, and strategic insights.

View Industry Page
;